SMA Typ 1-3: Biogen continues with new data in adults and infants

CAMBRIDGE, Mass., April 12, 2019 (GLOBE NEWSWIRE)Biogen (Nasdaq: BIIB) today announced it will present new data illustrating the rapidly progressive nature of spinal muscular atrophy (SMA) in adults, adolescents and older children at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida (April 13-17, 2019). Other Biogen presentations will highlight the benefits of pre-symptomatic treatment with data from the NURTURE study, part of the SPINRAZA® (nusinersen) global clinical trial program, and findings on the role of neurofilament as a potential biomarker for predicting motor function in SMA.

Publicerat av

Liz

Att acceptera vad som händer och låt trollen i ljuset, kanske du borde att tro mer på dig själv Liz Photopage Instagram

2 reaktioner till “SMA Typ 1-3: Biogen continues with new data in adults and infants”

  1. “The data show that, if left untreated, people with all types of SMA continue to experience increased health challenges, and that slowing the progression of the disease, even for those with less severe forms, is critical to their ongoing health,” said Wildon Farwell, M.D., senior medical director, clinical development at Biogen. “With more than 6,600 individuals treated with SPINRAZA across the post-marketing setting, expanded access program and clinical trials and over six years of clinical data, we continue to expand our in-depth knowledge of the disease and to gain real-world experience on long-term safety and efficacy. We plan to continue advancing research to help shape care for individuals with SMA today and in the future.”

    Read more about the new presentations on SMA and SPINRAZA
    http://investors.biogen.com/news-releases/news-release-details/biogen-continues-advance-innovation-sma-new-data-adults-and

    https://twitter.com/biogen/status/1116742807069310982

    #Behandlung mit Spinraza bei Erwachsenen

  2. New Data by Biogen Treatment with SPINRAZA resulted in clinically meaningful improvements in motor-function and survival in individuals with spinal muscular atrophy SMA Type 1, 2 or 3

    Data from CHERISH-SHINE, which evaluated individuals with later-onset SMA (n=125, most likely to develop SMA Type 2 or 3), demonstrated that earlier treatment resulted in greater improvements in motor function and continued improvement or stabilization of motor function scores. Mean change in Hammersmith Functional Motor Scale Expanded (HFSME) score was 3.7 for participants treated with SPINRAZA in SHINE and CHERISH. This compared to a positive 0.4 change from baseline among participants in the CHERISH sham-control arm and who received SPINRAZA in SHINE. During CHERISH, sham-control participants experienced a 0.4 decline in HFSME. Four participants in the youngest age group in the study (n=39, less than 3.69 years) were walking independently at Day 690 compared to no patients at baseline. There were no new safety findings. Patients were followed for up to four years, adding to the long-term safety profile of SPINRAZA.

    Data from the NURTURE study showed that pre-symptomatic treatment of infantile-onset SMA (n=25, most likely to develop SMA Type 1 or 2) resulted in motor milestone achievements more consistent with normal motor development. Evaluations were conducted at a median age of 26 months. All infants were able to sit without support and 88 percent could walk with assistance and 77 percent could walk without assistance. All infants were alive and none required permanent ventilation. No new safety concerns were identified. In the natural history of SMA, individuals are unable to sit without support (SMA Type 1) or walk (SMA Type 1 or 2) and often require respiratory and nutritional interventions in order to live past the age of two (SMA Type 1). The May 2018 data was previously presented.

Kommentarer inaktiverade.